Compare WEN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEN | OMER |
|---|---|---|
| Founded | 1969 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2001 | 2008 |
| Metric | WEN | OMER |
|---|---|---|
| Price | $8.61 | $13.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 20 | 3 |
| Target Price | $8.04 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 7.3M | 1.2M |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ 0.37 | 0.13 |
| Revenue | ★ $2,176,891,000.00 | $29,868,000.00 |
| Revenue This Year | $1.71 | N/A |
| Revenue Next Year | $0.57 | $66.13 |
| P/E Ratio | ★ $23.24 | $107.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.94 | $6.70 |
| 52 Week High | $9.45 | $21.24 |
| Indicator | WEN | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 68.64 | 31.39 |
| Support Level | $6.62 | $9.45 |
| Resistance Level | $9.30 | $19.68 |
| Average True Range (ATR) | 0.34 | 0.90 |
| MACD | 0.07 | -0.44 |
| Stochastic Oscillator | 77.57 | 12.03 |
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.